Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages

Autor: Gautiar, EL, Shay, T, Miller, J, Greter, M, Jakubzick, C, Ivanov, S, Helft, J, Chow, A, Elpek, KG, Gordonov, S, Mazloom, AR, Ma'Ayan, A, Chua, WJ, Hansen, TH, Turley, SJ, Merad, M, Randolph, GJ, Best, AJ, Knell, J, Goldrath, A, Brown, B, Jojic, V, Koller, D, Cohen, N, Brenner, M, Regev, A, Fletcher, A, Bellemare-Pelletier, A, Malhotra, D, Jianu, R, Laidlaw, D, Collins, J, Narayan, K, Sylvia, K, Kang, J, Gazit, R, Garrison, BS, Rossi, DJ, Kim, F, Rao, TN, Wagers, A, Shinton, SA, Hardy, RR, Monach, P, Bezman, NA, Sun, JC, Kim, CC, Lanier, LL, Heng, T, Kreslavsky, T, Painter, M, Ericson, J, Davis, S, Mathis, D, Benoist, C

Publikováno v: Gautiar, EL; Shay, T; Miller, J; Greter, M; Jakubzick, C; Ivanov, S; et al.(2012). Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nature Immunology, 13(11), 1118-1128. doi: 10.1038/ni.2419. UCSF: Retrieved from: http://www.escholarship.org/uc/item/50c349sc

We assessed gene expression in tissue macrophages from various mouse organs. The diversity in gene expression among different populations of macrophages was considerable. Only a few hundred mRNA transcripts were selectively expressed by macrophages r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::32edfa6f521adf6fefb4d2ddfe7b7a82
http://www.escholarship.org/uc/item/50c349sc

Analytical validation of a novel panel of biomarkers for a test for preeclampsia.

Autor: Hendershot JM; Progenity, Inc., 4330 La Jolla Village Dr., San Diego, CA 92122, United States. Electronic address: Jenna.Hendershot@progenity.com., Abbasi M; Progenity, Inc., 4330 La Jolla Village Dr., San Diego, CA 92122, United States., Fortier L; Progenity, Inc., 4330 La Jolla Village Dr., San Diego, CA 92122, United States., Benn M; Progenity, Inc., 4330 La Jolla Village Dr., San Diego, CA 92122, United States., Giacobone C; Progenity, Inc., 4330 La Jolla Village Dr., San Diego, CA 92122, United States., Del Mastro R; Progenity, Inc., 4330 La Jolla Village Dr., San Diego, CA 92122, United States., Bahrami-Samani E; Progenity, Inc., 4330 La Jolla Village Dr., San Diego, CA 92122, United States., Mazloom AR; Progenity, Inc., 4330 La Jolla Village Dr., San Diego, CA 92122, United States., Oberoi P; Progenity, Inc., 4330 La Jolla Village Dr., San Diego, CA 92122, United States.

Publikováno v: Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2022 May 30; Vol. 214, pp. 114729. Date of Electronic Publication: 2022 Mar 18.

Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible.

Autor: Jensen TJ; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California. jenset2@labcorp.com.; Laboratory Corporation of America, Durham, North Carolina., Goodman AM; Department of Medicine, Division of Hematology/Oncology, and Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego.; Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California, San Diego., Ellison CK; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California., Holden KA; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California., Kato S; Department of Medicine, Division of Hematology/Oncology, and Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego.; Department of Medicine, Division of Precision Medicine, Moores Cancer Center, University of California, San Diego., Kim L; Department of Medicine, Division of Hematology/Oncology, and Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego., Daniels GA; Department of Medicine, Division of Hematology/Oncology, and Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego., Fitzgerald K; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California., McCarthy E; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California., Nakashe P; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California., Mazloom AR; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California., Almasri E; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California., McLennan G; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California., Grosu DS; Sequenom, Inc, a wholly owned subsidiary of Laboratory Corporation of America Holdings, San Diego, California., Eisenberg M; Laboratory Corporation of America, Burlington, North Carolina., Kurzrock R; Department of Medicine, Division of Hematology/Oncology, and Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego.; Department of Medicine, Division of Precision Medicine, Moores Cancer Center, University of California, San Diego.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2021 Nov; Vol. 20 (11), pp. 2274-2279. Date of Electronic Publication: 2021 Aug 31.

An Esrrb and Nanog Cell Fate Regulatory Module Controlled by Feed Forward Loop Interactions.

Autor: Sevilla A; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Departament de Biología Cellular, Fisiología i Immunología, Facultat de Biología, Universitat de Barcelona, Barcelona, Spain., Papatsenko D; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Mazloom AR; Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Xu H; Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Vasileva A; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Unwin RD; Stem Cell and Leukaemia Proteomics Laboratory, School of Cancer and Enabling Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom.; Academic Health Science Centre, Wolfson Molecular Imaging Centre, Manchester, United Kingdom.; Centre for Advanced Discovery and Experimental Therapeutics, Central Manchester University Hospitals NHS Foundation Trust, Institute of Human Development, Faculty of Medical and Human Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom., LeRoy G; Department of Molecular Biology, Princeton University, Princeton, NJ, United States., Chen EY; Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Garrett-Bakelman FE; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States., Lee DF; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Trinite B; Institut de Recerca de La Sida, IrsiCaixa AIDS Research Institute, Germans Trias I Pujol Research Institute, Hospital Universitari Germans Trias I Pujol, Catalonia, Spain., Webb RL; Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Wang Z; Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Su J; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Gingold J; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Melnick A; Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, United States., Garcia BA; Department of Molecular Biology, Princeton University, Princeton, NJ, United States., Whetton AD; Stem Cell and Leukaemia Proteomics Laboratory, School of Cancer and Enabling Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom.; Academic Health Science Centre, Wolfson Molecular Imaging Centre, Manchester, United Kingdom., MacArthur BD; The Centre for Human Development, Stem Cells and Regeneration, Institute of Developmental Sciences, University of Southampton, Southampton, United Kingdom., Ma'ayan A; Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, United States., Lemischka IR; Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.; Department of Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Publikováno v: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2021 Mar 19; Vol. 9, pp. 630067. Date of Electronic Publication: 2021 Mar 19 (Print Publication: 2021).

Using Targeted Sequencing of Paralogous Sequences for Noninvasive Detection of Selected Fetal Aneuploidies.

Autor: Ellison CK; Sequenom Laboratories and., Sun Y; Sequenom Laboratories and., Hogg G; Sequenom Laboratories and., Fox J; Sequenom Laboratories and., Tao H; Sequenom Laboratories and., McCarthy E; Sequenom Laboratories and., Sagoe B; Sequenom Laboratories and., Azab MA; Sequenom Laboratories and., Mazloom AR; Sequenom Laboratories and., Tynan J; Sequenom Laboratories and., Burcham T; Sequenom, Inc., San Diego, California., Kim SK; Sequenom Laboratories and., van den Boom D; Sequenom, Inc., San Diego, California., Ehrich M; Sequenom, Inc., San Diego, California., Jensen TJ; Sequenom Laboratories and tjensen@sequenom.com.

Publikováno v: Clinical chemistry [Clin Chem] 2016 Dec; Vol. 62 (12), pp. 1621-1629. Date of Electronic Publication: 2016 Sep 30.